BSE filing, BSE: 542678. Summary written from the filing by ALFA Finder's alert engine.
Cian Healthcare Ltd: key numbers
- Share price
- ₹32.20
- Market cap
- ₹80.50 Cr
- Revenue (annual)
- ₹28.30 Cr
- Net profit (annual)
- ₹-23.29 Cr
- Promoter holding
- 95.00%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Cian Healthcare Ltd
All →Cian Healthcare Merger & Restructuring
Cian Healthcare disposed of its Dr. Smiths Biotech subsidiary under an NCLT-approved resolution plan. Its equity was cancelled with nil consideration receivable.
Cian Healthcare Insolvency Petition
Cian Healthcare's subsidiary Dr. Smiths Biotech ceased to be a subsidiary after NCLT approved Ananta Medicare's resolution plan. Equity was extinguished with no consideration received.
Cian Healthcare Management Change
Cian Healthcare Limited has appointed M/s. Rasool Singhal & Co. as the new Statutory Auditor for a term of 60 months.
Cian Healthcare Annual General Meeting
Cian Healthcare Ltd held its 23rd AGM on September 29, 2026, approving financial statements, director re-appointment, auditor appointment, and the 2026 Employee Stock Option Scheme.
Cian Healthcare Annual Report
Cian Healthcare Limited has filed its Annual Report for the financial year ended March 31, 2026, and the Notice of its 23rd Annual General Meeting.
Cian Healthcare Employee Stock Options
Cian Healthcare has instituted an Employee Stock Option Scheme (ESOS 2026), covering up to 10 million shares. No grants have been issued yet under this plan.
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.